AlzeCure and Eli Lilly Partner on Alzheimer’s Drug ACD680
STOCKHOLM, Sweden, June 9, 2026 AlzeCure Pharma announced a global collaboration and out-licensing agreement with Eli Lilly and Company...
Licensing Agreement
Advertisement
Innovent’s IBI343 Shows Strong Efficacy in Phase III Study, Eyes Regulatory Approval
SAN FRANCISCO and SUZHOU, China, June 4, 2026 Innovent Biologics has announced a major breakthrough in precision oncology as...
CytomX and Regeneron Expand $4B Cancer Immunotherapy Alliance
SOUTH SAN FRANCISCO, California, USA, June 3, 2026 CytomX Therapeutics has announced a significant expansion of its strategic research...
Travere Licenses Civorebrutinib in $1.14B Kidney Disease Deal
SAN DIEGO, California, USA, June 2, 2026 Travere Therapeutics has significantly expanded its rare kidney disease pipeline through an...
Ascidian and Lilly Sign $1.9B Kidney Disease RNA Deal
BOSTON, Massachusetts, USA, June 3, 2026 Ascidian Therapeutics and Eli Lilly and Company have entered into a landmark global...
Advertisements
Pfizer and Innovent Forge $10.5B Global Oncology Alliance
NEW YORK, SAN FRANCISCO, and SUZHOU, China, May 28, 2026 Pfizer Inc. and Innovent Biologics have announced a landmark...
Polpharma Biologics and Tuteur Sign LATAM Autoimmune Biosimilar Deal
WARSAW, Poland and BUENOS AIRES, Argentina, 22 May 2026 Polpharma Biologics has entered a major licensing agreement with Tuteur...
AstraZeneca and Daiichi Sankyo Secure FDA Approval for Enhertu in Early HER2 Breast Cancer
WILMINGTON, Del., May 15, 2026 AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA)...
SERB and Hansa Biopharma Strengthen Rare Disease Portfolio With Idefirix Agreement
BRUSSELS, Belgium, May 19, 2026 SERB Pharmaceuticals and Hansa Biopharma have announced a strategic €115 million licensing agreement granting...
BMS and Hengrui Form $15 Billion Drug Development Alliance
SHANGHAI, China and PRINCETON, N.J., May 12, 2026 Hengrui Pharma and Bristol Myers Squibb (BMS) have announced a landmark...
Advertisement
